SCHEMBL2436359

SCHEMBL2436359

CC(C)(C)[C@H](NC(=O)O)C(=O)N[C@@H](Cc1ccc(-c2ccccn2)cc1)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CO)C(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.60
CTSD P07339 4/20 0.60
UGT1A1 P22309 3/20 0.57
ABCB11 O95342 2/20 0.57
ABCB1 P08183 2/20 0.57
ABCG2 Q9UNQ0 2/20 0.57
MLNR O43193 1/20 0.57
NR1I2 O75469 1/20 0.57
SLCO2B1 O94956 1/20 0.57
CCKAR P32238 1/20 0.57
OPRK1 P41145 1/20 0.57
GHSR Q92847 1/20 0.57
SLCO1B3 Q9NPD5 1/20 0.57
SLCO1B1 Q9Y6L6 1/20 0.57
CA2 P00918 1/20 0.49
KCNH2 Q12809 2/20 0.45
MME P08473 2/20 0.40
ABCC3 O15438 1/20 0.39
ABCC4 O15439 1/20 0.39
PGR P06401 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435672 0.92 CYP3A4 (0.62) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL2435668 0.92 CYP3A4 (0.62) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL2437193 0.91 CYP3A4 (0.62) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL2436292 0.91 CYP3A4 (0.60) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL3808854 0.90 CTSD (0.60) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL2433927 0.90 CYP3A4 (0.72) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL2435212 0.90 CYP3A4 (0.72) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL3804570 0.90 CYP3A4 (0.72) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL2435678 0.90 CYP3A4 (0.72) CYP3A4CTSDUGT1A1ABCB11ABCB1
SCHEMBL3803571 0.90 CYP3A4 (0.72) CYP3A4CTSDUGT1A1ABCB11ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140194349-A1 HIV Protease Inhibiting Compounds ABBVIE INC. (US) 2014-07-10 US claimed
EP-1697344-B1 HIV PROTEASE INHIBITING COMPOUNDS ABBOTT LAB (US) 2011-09-28 EP claimed
US-20140194349-A1 HIV Protease Inhibiting Compounds ABBVIE INC. (US) 2014-07-10 US disclosed
EP-2266971-A2 Hiv protease inhibiting compounds Abbott Laboratories (US) 2010-12-29 EP disclosed
US-20050148623-A1 Prevent reproduct of aids virus ABBVIE INC. 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148623-A1 Prevent reproduct of aids virus SERPINB1, PRSS1, SERPINA3 CYP3A4 481/4885CTSD 146/4885UGT1A1 1234/4885
US-20140194349-A1 HIV Protease Inhibiting Compounds SERPINB1, HPN, DNPEP CYP3A4 764/4885CTSD 84/4885UGT1A1 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.